CapsoVision (CV) Registration filing summary

Company overview and business model

• Global commercial-stage medical technology company focused on diagnostic and screening products for GI tract abnormalities, leveraging advanced imaging and AI technologies.

• Flagship product is the CapsoCam capsule endoscopy system, with over 176,000 patients served as of June 30, 2026.

• CapsoCam Plus is FDA-cleared for small bowel visualization in adults and children, with ongoing updates to incorporate AI-assisted pathology detection.

• Pipeline includes CapsoCam Colon (second generation in pivotal study) and CapsoCam UGI for early pancreatic cancer detection.

• Sales are conducted in the U.S. via an in-house team and internationally through distributors; 21% of 2025 revenue was from international sales.

Financial performance and metrics

• Revenue for the six months ended June 30, 2026: $6.4 million, up 6% from $6.1 million in the prior year period.

• Full-year revenue for 2025: $13.6 million, up 15% from $11.8 million in 2024.

• Revenue growth driven by increased CapsoCam Plus sales since U.S. direct sales began in 2020.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including sales and marketing, R&D, general and administrative matters, and working capital.

• Pending specific use, proceeds may be temporarily invested in money market funds.